Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer
bioRxiv preprint doi: https://doi.org/10.1101/2020.09.13.291328; this version posted September 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Subtype Heterogeneity and Epigenetic Convergence in Neuroendocrine Prostate Cancer Paloma Cejas1,2,3, Yingtian Xie1,2, Alba Font-Tello1,2, Klothilda Lim1,2, Sudeepa Syamala1,2, Xintao Qiu1,2, Alok K. Tewari1,2,4, Neel Shah1,2, Holly M Nguyen5, Radhika A. Patel6, Lisha Brown5, Ilsa Coleman6, Wenzel M. Hackeng7, Lodewijk Brosens7, Koen M.A. Dreijerink8, Leigh Ellis4,9, Sarah Abou Alaiwi1, Ji-Heui Seo1, Mark Pomerantz1, Alessandra Dall'Agnese10, Jett Crowdis1,4, Eliezer M. Van Allen1,4, Joaquim Bellmunt11, Colm Morrisey5, Peter S. Nelson6, James DeCaprio1, Anna Farago12, Nicholas Dyson12, Benjamin Drapkin13,14,15, X. Shirley Liu2,16, Matthew Freedman1,2, Michael C. Haffner6,17,18, Eva Corey5, Myles Brown1,2* and Henry W. Long1,2* 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts, USA. 2. Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 3. Translational Oncology Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ) and CIBERONC, La Paz University Hospital, Madrid, Spain. 4. Broad Institute of MIT and Harvard, Cambridge, MA, USA 5. Department of Urology, University of Washington, Seattle, WA, USA 6. Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 7.
[Show full text]